Ian S Hagemann1. 1. From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri. Presented at the 2nd Princeton Integrated Pathology Symposium: Breast Pathology; February 8, 2015; Plainsboro, New Jersey.
Abstract
CONTEXT: -Molecular diagnostics play a role in the management of many cancers, including breast cancer. OBJECTIVE: -To provide an update on molecular testing in current clinical practice, targeted at practicing pathologists who are not breast cancer specialists. DATA SOURCES: -This study is a narrative literature review. CONCLUSIONS: -In addition to routine hormone (estrogen and progesterone) receptor testing, new and recurrent tumors are tested for HER2 amplification by in situ hybridization or overexpression by immunohistochemistry. Intrinsic subtyping of tumors represents a fundamental advance in our understanding of breast cancer biology, but currently it has an indirect role in patient management. Clinical next-generation sequencing (tumor profiling) is increasingly used to identify potentially actionable mutations in tumor tissue. Multianalyte assays with algorithmic analysis, including MammaPrint, Oncotype DX, and Prosigna, play a larger role in breast cancer than in many other malignancies. Given that a proportion of breast cancers are familial, testing of nontumor tissue for cancer predisposition mutations also plays a role in breast cancer care.
CONTEXT: -Molecular diagnostics play a role in the management of many cancers, including breast cancer. OBJECTIVE: -To provide an update on molecular testing in current clinical practice, targeted at practicing pathologists who are not breast cancer specialists. DATA SOURCES: -This study is a narrative literature review. CONCLUSIONS: -In addition to routine hormone (estrogen and progesterone) receptor testing, new and recurrent tumors are tested for HER2 amplification by in situ hybridization or overexpression by immunohistochemistry. Intrinsic subtyping of tumors represents a fundamental advance in our understanding of breast cancer biology, but currently it has an indirect role in patient management. Clinical next-generation sequencing (tumor profiling) is increasingly used to identify potentially actionable mutations in tumor tissue. Multianalyte assays with algorithmic analysis, including MammaPrint, Oncotype DX, and Prosigna, play a larger role in breast cancer than in many other malignancies. Given that a proportion of breast cancers are familial, testing of nontumor tissue for cancer predisposition mutations also plays a role in breast cancer care.
Authors: Achal Patel; Montserrat García-Closas; Andrew F Olshan; Charles M Perou; Melissa A Troester; Michael I Love; Arjun Bhattacharya Journal: Cancer Res Date: 2021-10-28 Impact factor: 12.701
Authors: Gábor Cserni; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Erika Tóth; Nóra Udvarhelyi; László Vass; András Vörös; Ana Krivokuca; Karol Kajo; Katarína Kajová Macháleková; Janina Kulka Journal: Pathol Oncol Res Date: 2022-06-27 Impact factor: 2.874
Authors: Swati Gupta; Navin R Mani; Daniel E Carvajal-Hausdorf; Veerle Bossuyt; Kenneth Ho; Jodi Weidler; Wendy Wong; Brian Rhees; Michael Bates; David L Rimm Journal: Lab Invest Date: 2018-06-01 Impact factor: 5.662
Authors: Brad E Wasserman; Daniel E Carvajal-Hausdorf; Kenneth Ho; Wendy Wong; Natalie Wu; Victor C Chu; Edwin W Lai; Jodi M Weidler; Michael Bates; Veronique Neumeister; David L Rimm Journal: Lab Invest Date: 2017-09-11 Impact factor: 5.662
Authors: Alberto Peláez-García; Laura Yébenes; Alberto Berjón; Antonia Angulo; Pilar Zamora; José Ignacio Sánchez-Méndez; Enrique Espinosa; Andrés Redondo; Victoria Heredia-Soto; Marta Mendiola; Jaime Feliú; David Hardisson Journal: PLoS One Date: 2017-09-08 Impact factor: 3.240